Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Process Sensing Technologies Has Been Acquired by DwyerOmega

    William Blair acted as financial advisor to Process Sensing Technologies, a portfolio company of AEA Investors, in connection with its sale to DwyerOmega, a portfolio company of Arcline Investment Management.

    Read more

  • Reducing Real-World Emissions

    Shivani Patel, a sustainability analyst on our U.S. growth and core equity team, discusses what she learned at a sustainability conference about the push to reduce real-world emissions.

    Watch the video

  • Risk: Understanding and Managing an Inevitable Part of Investing

    Identifying the various types of risk that investors face can help you think strategically about how to manage risk in a way that aligns with your goals and objectives.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures